US2010260761A1PendingUtilityA1

Antibodies specifically reactive with a tumor necrosis factor related ligand

67
Assignee: BIOGEN INCPriority: Aug 7, 1996Filed: Jun 5, 2006Published: Oct 14, 2010
Est. expiryAug 7, 2016(expired)· nominal 20-yr term from priority
Inventors:Jeffrey BrowningYves Chicheportiche
A61K 38/00A61K 39/395C12N 2799/026C07K 2319/00A61K 48/00A61P 37/00C07K 14/705
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to antibodies that bind Tumor Necrosis Factor Related Ligand (TRELL), a novel member of the tumor necrosis factor family (TNF), modified TRELL, and pharmaceutical compositions comprising them.

Claims

exact text as granted — not AI-modified
1 . A substantially pure antibody or antigen-binding portion thereof that is specifically reactive with a polypeptide that is at least 90% identical with amino acids 36 to 284 of SEQ ID NO:4. 
     
     
         2 . The antibody or antigen-binding portion thereof, according to  claim 1 , wherein the polypeptide is capable of binding to and inducing apoptosis in an HT29 colon carcinoma cell. 
     
     
         3 . The antibody or antigen-binding portion thereof, according to  claim 1 , that is specifically reactive with a polypeptide that is at least 95% identical with amino acids 36 to 284 of SEQ ID NO:4. 
     
     
         4 . The antibody or antigen-binding portion thereof, according to  claim 3 , that is specifically reactive with a polypeptide that is at least 95% identical with amino acids 81 to 284 of SEQ ID NO:4. 
     
     
         5 . The antibody or antigen-binding portion thereof, according to  claim 3 , that is specifically reactive with a polypeptide that is at least 95% identical with amino acids 139 to 284 of SEQ ID NO:4. 
     
     
         6 . A substantially pure antibody or antigen-binding portion thereof that is specifically reactive with a polypeptide that is at least 90% identical to SEQ ID NO:2. 
     
     
         7 . The antibody or antigen-binding portion thereof, according to  claim 6 , that is specifically reactive with a polypeptide that is at least 95% identical to SEQ ID NO:2. 
     
     
         8 . The antibody or antigen-binding portion thereof, according to  claim 6 , wherein the polypeptide is capable of binding to and inducing apoptosis in an HT29 colon carcinoma cell. 
     
     
         9 . The antibody or antigen-binding portion thereof, according to  claim 6 , that is specifically reactive with a polypeptide that is at least 95% identical to amino acids 22 to 225 of SEQ ID NO:2. 
     
     
         10 . The antibody or antigen-binding portion thereof, according to  claim 6 , that is specifically reactive with a polypeptide that is at least 95% identical to amino acids 80 to 225 of SEQ ID NO:2. 
     
     
         11 . A substantially pure antibody that comprises human constant domains and that is specifically reactive with amino acids 81 to 284 of SEQ ID NO:4. 
     
     
         12 . The antibody or antigen-binding portion thereof according to  claim 1 , wherein said antibody or antigen-binding portion thereof is a monoclonal antibody. 
     
     
         13 . The antibody or antigen-binding portion thereof according to  claim 1 , wherein said antibody or antigen-binding portion thereof is a polyclonal antibody. 
     
     
         14 . The antibody or antigen-binding portion thereof according to  claim 1  that is an antibody fragment. 
     
     
         15 . The antibody or antigen-binding portion thereof according to  claim 1 , wherein said antibody or antigen-binding portion thereof is a chimeric antibody. 
     
     
         16 . The antibody or antigen-binding portion thereof according to  claim 1 , wherein said antibody or antigen-binding portion thereof is a humanized antibody. 
     
     
         17 . An antibody according to  claim 1 , wherein said antibody comprises human constant domains. 
     
     
         18 . The antibody or antigen-binding portion thereof according to  claim 1 , wherein said antibody or antigen-binding portion thereof is a recombinant antibody. 
     
     
         19 . The antibody or antigen-binding portion thereof according to  claim 1  that is a Fab′ fragment. 
     
     
         20 . The antibody or antigen-binding portion thereof according to  claim 1  that is a F(ab′)2 fragment. 
     
     
         21 . A composition comprising the antibody or antigen-binding portion thereof according to  claim 1  and a pharmaceutically acceptable carrier. 
     
     
         22 . A method for producing an antibody, the method comprising:
 immunizing an animal with a polypeptide comprising a sequence that is at least 90% identical to amino acids 81 to 284 of SEQ ID NO:4 or to amino acids 22 to 225 of SEQ ID NO:2, or an immunogenic portion thereof.   
     
     
         23 . The method of  claim 22  wherein the polypeptide comprises a sequence that is at least 95% identical to amino acids 81 to 284 of SEQ ID NO:4, or an immunogenic portion thereof. 
     
     
         24 . The method of  claim 22  wherein the polypeptide comprises a sequence that is at least 95% identical to amino acids 22 to 225 of SEQ ID NO:2, or an immunogenic portion thereof.

Join the waitlist — get patent alerts

Track US2010260761A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.